Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0IDOUS)
| ADC Name |
MK-6204
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
MK-6204; SKB535
Click to Show/Hide
|
|||||
| Organization |
Kelun Biotherapeutics (Originator);Merck & Co. (Top20 MNC)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
Undisclosed
|
|||||
| Payload Target |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Oesophageal cancer |
1 Trials
|
|||||
| Gastroesophageal junction adenocarcinoma |
1 Trials
|
|||||
| Gastric cancer |
1 Trials
|
|||||
| Colorectal cancer |
1 Trials
|
|||||
| Pancreatic cancer |
1 Trials
|
|||||
| Lung cancer |
1 Trials
|
|||||
| Cervical cancer |
1 Trials
|
|||||
| Head and neck cancer |
1 Trials
|